Data presented at the 13th Annual Meeting of Connective Tissue Oncology Society held in Seattle, Washington demonstrates clinical activity and
tolerability of perifosine as a single agent in patients with
NEW YORK, Nov. 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that preliminary data demonstrating the tolerability and clinical activity of KRX-0401 (perifosine) in patients with refractory, rare sarcomas was presented on Saturday, November 3, 2007 at the Annual Meeting of the Connective Tissue Oncology Society.
In an oral presentation entitled "A PHASE II TRIAL OF PERIFOSINE IN PATIENTS WITH CHEMO-INSENSITIVE SARCOMAS: PRELIMINARY RESULTS," Dr. Joseph Ludwig Assistant Professor, Dept of Sarcoma, MD Anderson Cancer Center reported on preliminary Phase 2 data in which single agent perifosine demonstrated a 40% overall clinical benefit (Stable Disease > 3 months) in these subsets of patients. Assessment of response was completed by both, RECIST and Choi criteria, and results by sarcoma subtype as follows:
Sarcoma Histology Evaluable PR (Choi) SD > 12 wks
Patients N (%) N (%)
Chondrosarcoma 25 1 (4%) 5 (20%)
Extra-Skeletal Myxoid 13 2 (15%) 5 (38%)
Alveolar Soft Part 10 3 (30%) 3 (30%)
TOTAL 48 6 (13%) 13 (27%)
Perifosine was also well tolerated with the most common grade 1 & 2 adverse events reported as nausea, vomiting, diarrhea and fatigue.
|SOURCE Keryx Biopharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved